Congenia Overview

  • Founded
  • 2004
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

Congenia General Information


Developer of biopharmaceutical drugs designed to target the mitochondrial permeability transition pore.The company's drugs are focused on developing inhibitors to stop the mitochondrial permeability transition that can lead to cell death, enabling patients and medical practitioners to clinically validate the pathogenesis of several diseases and other indications.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Primary Office
  • Via Privata Giovannino De Grassi, 11
  • 20123 Milan
  • Italy
+39 02 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Congenia Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 18-Jun-2021 Completed Out of Business
1. Buyout/LBO Completed Startup
To view Congenia’s complete valuation and funding history, request access »